Concurrent Drug-induced Rowell Syndrome and Acute Generalized Exanthematous Pustulosis

Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol 2012; 67: 417–421. DOI: https://doi.org/10.1016/j.jaad.2011.10.012

Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18: 935–940. DOI: https://doi.org/10.1177/0961203309106176

Herold M, Nielson CB, Braswell D, Merkel K, Walker A, Auerbach J, et al. Clinicopathologic comparison of Rowell syndrome, erythema multiforme, and subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2019; 81: 1435–1438. DOI: https://doi.org/10.1016/j.jaad.2019.06.008

Siegel CH, Sammaritano LR. Systemic lupus erythematosus: a review. JAMA 2024; 331: 1480–1491. DOI: https://doi.org/10.1001/jama.2024.2315

Kacalak-Rzepka A, Kiedrowicz M, Bielecka-Grzela S, Ratajczak- Stefanska V, Maleszka R, Mikulska D. Rowell’s syndrome in the course of treatment with sodium valproate: a case report and review of the literature data. Clin Exp Dermatol 2009; 34: 702–704. DOI: https://doi.org/10.1111/j.1365-2230.2008.02972.x

Murad A, Shudell E, Mulligan N. Rowell’s syndrome induced by terbinafine. BMJ Case Rep 2015; 2015: bcr2015210360. DOI: https://doi.org/10.1136/bcr-2015-210360

Pozharashka J, Dourmishev L, Balabanova M, Vassileva S, Miteva L. Rowell’s syndrome triggered by omeprazole. Acta Dermatovenerol Croat 2019; 27: 124–126.

Baroni A, Piccolo V, Russo T, Cozzolino D, Mascolo M, Chessa MA. Norfloxacin-induced subacute cutaneous lupus with erythema multiforme-like lesions: the enigma of the Rowell syndrome. J Dtsch Dermatol Ges 2014; 12: 1039–1042. DOI: https://doi.org/10.1111/ddg.12392

Champagne C, Ratnavel R, Wong T. Severe Rowell syndrome associated with oral terbinafine. Clin Exp Dermatol 2012; 37: 822–823. DOI: https://doi.org/10.1111/j.1365-2230.2012.04363.x

Schissler C, Banea S, Tortel MC, Mahé A. Un nouveau cas de syndrome de Rowell. Ann Dermatol Venereol 2017; 144: 263–267. DOI: https://doi.org/10.1016/j.annder.2017.02.005

Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JNB, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989–996. DOI: https://doi.org/10.1111/j.1365-2133.2007.08156.x

GE, Johnston GA, Mortimer NJ, Harman KE. Acute generalized exanthematous pustulosis associated with azathioprine hypersensitivity. Clin Exp Dermatol 2007; 32: 52–53.

Parisi R, Shah H, Navarini AA, Muehleisen B, Ziv M, Shear NH, et al. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management. Am J Clin Dermatol 2023; 24: 557–575. DOI: https://doi.org/10.1007/s40257-023-00779-3

Avgerinos A, Giannikaki E, Krüger-Krasagakis S, Koutroubakis IE. Acute generalized exanthematous pustulosis induced by azathioprine in a patient with ulcerative colitis. Am J Gastroenterol 2011; 106: 1005–1007. DOI: https://doi.org/10.1038/ajg.2010.500

Chang C, Gershwin ME. Drugs and autoimmunity--a contemporary review and mechanistic approach. J Autoimmun 2010; 34: J266–75. DOI: https://doi.org/10.1016/j.jaut.2009.11.012